{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:45:30Z","timestamp":1762659930341},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Catatonia is a widespread problem in psychiatric hospitals as approximately 10% of patients present with catatonic symptoms upon admission. Catatonia carries the risk of severe, even fatal complications. The first line treatment is usually electroconvulsive therapy (ECT) or benzodiazepines, but ECT may not be readily available and benzodiazepines may not always be effective. We describe the case of a patient presenting with severe symptoms of catatonic depression who completed a 3-day course of 25\u00a0mg aripiprazole that rapidly resolved his catatonic symptoms. Several cases have already been reported where administration of aripiprazole successfully resolved catatonic symptoms after other treatment options had failed. Aripiprazole\u2019s efficacy and advantages may lie in its unique receptor profile. It acts as a dopamine D2 receptor (D2\u00a0R) antagonist and partial D2\u00a0R agonist depending on the precise cellular milieu, which may explain its efficacy and favourable side effect profile compared to other antipsychotics used to treat catatonia. Aripiprazole also partially agonises D3 receptors and serotonin 2\u00a0C receptors (5-HT2\u00a0C), which may contribute to its antidepressant properties. Aripiprazole enhances gamma-aminobutyric acid (GABA) transmission in certain brain areas, and it is widely agreed that low GABA activity may contribute to catatonic symptoms. Pharmacokinetics studies show that peak plasma levels are reached rapidly, within 2\u20133\u00a0hours of intramuscular administration and 4\u20136\u00a0hours of oral administration. Administration of high-dose aripiprazole (&gt;25\u00a0mg\/day) should be considered as a viable alternative to ECT and benzodiazepines in patients presenting with catatonic symptoms. Aripiprazole also carries a much lower risk of complications compared to other antipsychotics.<\/jats:p>","DOI":"10.1055\/a-1183-3887","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:07:51Z","timestamp":1592953671000},"page":"178-181","source":"Crossref","is-referenced-by-count":6,"title":["Rapid efficacy of aripiprazole in the treatment of catatonic depression\/catatonia with consideration of the drug\u2019s unique receptor profile: a case report"],"prefix":"10.1055","volume":"89","author":[{"given":"Verena","family":"Sichert","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie Psychotherapie und Psychosomatische Medizin Schloss Werneck"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie Psychotherapie und Psychosomatische Medizin Schloss Werneck"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.psychres.2015.07.020","article-title":"Catatonia in inpatients with psychiatric disorders: A comparison of schizophrenia and mood disorders","volume":"229","author":"S Grover","year":"2015","journal-title":"Psychiatry Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/YCT.0b013e3181fe28bd","article-title":"Catatonia in diagnostic and statistical manual of mental disorders, fifth edition","volume":"26","author":"A Francis","year":"2010","journal-title":"J Ect"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/PSY.0000000000000574","article-title":"Catatonic Stupor in Schizophrenic Disorders and Subsequent Medical Complications and Mortality","volume":"80","author":"M Funayama","year":"2018","journal-title":"Psychosom Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5498\/wjp.v5.i2.182","article-title":"Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response","volume":"5","author":"F Luchini","year":"2015","journal-title":"World J Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3371\/CSRP.4.3.5","article-title":"Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: A case report","volume":"4","author":"E Kirino","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref6","first-page":"373","article-title":"Use of aripiprazole in the treatment of catatonia","volume":"12","author":"V Voros","year":"2010","journal-title":"Neuropsychopharmacologia Hungarica: A Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fpsyt.2015.00182","article-title":"Neurobiological approach of catatonia and treatment perspectives","volume":"6","author":"P Ellul","year":"2015","journal-title":"Front Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4306\/pi.2013.10.1.75","article-title":"Is the GABA system related to the social competence improvement effect of Aripiprazole? An (18)F-Fluoroflumazenil PET study","volume":"10","author":"JS Lee","year":"2013","journal-title":"Psychiatry Investig"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/yct.0b013e3181587949","article-title":"Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms","volume":"23","author":"K Hatta","year":"2007","journal-title":"J Ect"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2014.10.014","article-title":"New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gbetagamma signaling","volume":"93","author":"TF Brust","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/13543784.16.6.771","article-title":"Aripiprazole acts as a selective dopamine D2 receptor partial agonist","volume":"16","author":"M Wood","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"DA Shapiro","year":"2003","journal-title":"Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","journal-title":"Curr Pharm Des"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D(3) receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"GM Leggio","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"14.","DOI":"10.4088\/PCC.12m01386","article-title":"Aripiprazole partial agonism at 5-HT2C: A comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities","author":"CT Nguyen","year":"2012","journal-title":"Primary Care Companion CNS Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2515\/therapie:2005065","article-title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies","volume":"60","author":"MJ Millan","year":"2005","journal-title":"Therapie"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2050313\u00a0\u00d7\u00a017692936","DOI":"10.1177\/2050313X17692936","article-title":"Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases","volume":"5","author":"K Muneoka","year":"2017","journal-title":"SAGE Open Med Case Reports"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1183-3887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T05:11:03Z","timestamp":1618549863000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1183-3887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":17,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1183-3887","relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}